South Korea · Delayed Price · Currency is KRW REMEDI Statistics
Total Valuation
REMEDI has a market cap or net worth of KRW 133.83 billion. The enterprise value is 143.36 billion.
| Market Cap | 133.83B |
| Enterprise Value | 143.36B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
REMEDI has 7.63 million shares outstanding. The number of shares has increased by 0.18% in one year.
| Current Share Class | 7.63M |
| Shares Outstanding | 7.63M |
| Shares Change (YoY) | +0.18% |
| Shares Change (QoQ) | -0.18% |
| Owned by Insiders (%) | 52.32% |
| Owned by Institutions (%) | n/a |
| Float | 3.64M |
Valuation Ratios
The trailing PE ratio is 12.45.
| PE Ratio | 12.45 |
| Forward PE | n/a |
| PS Ratio | 5.88 |
| PB Ratio | 8.38 |
| P/TBV Ratio | 8.52 |
| P/FCF Ratio | 93.68 |
| P/OCF Ratio | 56.50 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.49, with an EV/FCF ratio of 100.35.
| EV / Earnings | 15.89 |
| EV / Sales | 6.30 |
| EV / EBITDA | 16.49 |
| EV / EBIT | 18.21 |
| EV / FCF | 100.35 |
Financial Position
The company has a current ratio of 1.44, with a Debt / Equity ratio of 0.70.
| Current Ratio | 1.44 |
| Quick Ratio | 0.98 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | 1.29 |
| Debt / FCF | 7.83 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 38.26% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 464.71M |
| Profits Per Employee | 184.10M |
| Employee Count | 49 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.41B |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 59.35 |
| Average Volume (20 Days) | 2,885,519 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, REMEDI had revenue of KRW 22.77 billion and earned 9.02 billion in profits. Earnings per share was 1,409.09.
| Revenue | 22.77B |
| Gross Profit | 13.73B |
| Operating Income | 7.87B |
| Pretax Income | 7.75B |
| Net Income | 9.02B |
| EBITDA | 8.69B |
| EBIT | 7.87B |
| Earnings Per Share (EPS) | 1,409.09 |
Balance Sheet
The company has 1.90 billion in cash and 11.18 billion in debt, with a net cash position of -9.28 billion or -1,216.67 per share.
| Cash & Cash Equivalents | 1.90B |
| Total Debt | 11.18B |
| Net Cash | -9.28B |
| Net Cash Per Share | -1,216.67 |
| Equity (Book Value) | 15.98B |
| Book Value Per Share | 2,462.70 |
| Working Capital | 5.24B |
Cash Flow
In the last 12 months, operating cash flow was 2.37 billion and capital expenditures -940.07 million, giving a free cash flow of 1.43 billion.
| Operating Cash Flow | 2.37B |
| Capital Expenditures | -940.07M |
| Depreciation & Amortization | 817.33M |
| Net Borrowing | 120.87M |
| Free Cash Flow | 1.43B |
| FCF Per Share | 187.33 |
Margins
Gross margin is 60.28%, with operating and profit margins of 34.58% and 39.62%.
| Gross Margin | 60.28% |
| Operating Margin | 34.58% |
| Pretax Margin | 34.05% |
| Profit Margin | 39.62% |
| EBITDA Margin | 38.17% |
| EBIT Margin | 34.58% |
| FCF Margin | 6.27% |
Dividends & Yields
REMEDI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.18% |
| Shareholder Yield | -0.18% |
| Earnings Yield | 6.74% |
| FCF Yield | 1.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REMEDI has an Altman Z-Score of 1.67 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.67 |
| Piotroski F-Score | 4 |